Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), impacting current treatment of nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer (HSPC). Continued development of the hormonal therapies, plus the development of targeted agents (e.g., Janssen / GlaxoSmithKline’s Zejula, Pfizer’s Talzenna), antibody-drug conjugates (MacroGenics’ vobramitamab duocarmazine), and novel prostate-specific membrane antigen (PSMA)-targeted radioligands (e.g., Novartis’s Pluvicto and POINT Biopharma’s 177Lu-PNT2002) will drive robust market growth over the 2022-2032 forecast period.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.